MedTrace Logo

Prospective Study on Primary Aldosteronism in Resistant Hypertension

NCT04213963 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-11-03

No results posted yet for this study

Summary

Prevalence of primary aldosteronism (PA) in resistant hypertension is not clear. In addition, emerging evidence supports the role of elevated serum aldosterone in promoting cardiovascular disease, independently from high blood pressure (BP) levels, but current data on this issue are heterogeneous.

Conditions

  • Resistant Hypertension
  • Primary Aldosteronism
  • Refractory Hypertension
  • Hypertensive End-Organ Damage
  • Atrial Fibrillation
  • Aortic Ectasia

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Principal Investigators

  • Mauro M Maccario, MD · Endocrinology, Diabetology and Metabolism; University of Turin

  • Ezio E Ghigo, MD · Endocrinology, Diabetology and Metabolism; University of Turin

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-01
Primary Completion
2020-09-30
Completion
2025-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04213963 on ClinicalTrials.gov